BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

Rhea-AI Summary

Bon Natural Life (Nasdaq: BON) announced a strategic Cooperation Framework Agreement with Tigerbone Group on February 4, 2026 to collaborate on traditional Chinese medicine, life sciences research, and nutritional functional foods. The parties will form the BON Cooperation and Development Committee to coordinate resource sharing and joint product development.

Each party will retain its independent intellectual property while jointly developing new products, technologies, and solutions to support BON's global growth strategy across China, North America, EU, Japan, and South Korea.

Positive

• Agreement signed on February 4, 2026
• BON Cooperation and Development Committee to centralize collaboration
• Collaboration scope includes TCM, life sciences, and nutritional foods
• Global footprint leverages BON presence in China, North America, EU, Japan, South Korea
• Independent IP retained while developing joint products

Negative

• No financial terms or revenue targets disclosed, limiting near-term financial visibility

News Market Reaction – BON

-0.76% 2.2x vol

11 alerts

-0.76% Session close to close

-17.8% Trough in 3 hr 7 min

$11.22M Market Cap

2.2x Rel. Volume

In the Mar 31 session, BON declined 0.76%, reflecting a mild negative market reaction. Argus tracked a trough of -17.8% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands BON’s collaboration strategy through a framework agreement with Tigerbone ...

Analysis

This announcement expands BON’s collaboration strategy through a framework agreement with Tigerbone Group and the planned “BON Cooperation and Development Committee.” The focus spans traditional Chinese medicine, life sciences, and nutritional functional foods while preserving each party’s intellectual property. In context of earlier R&D and sales partnerships and an effective shelf to register up to $500,000,000, investors may watch for concrete product launches, contracted volumes, and margin trends to assess long-term impact.

Key Figures

Company founding year: 2006

1 metrics

Company founding year 2006 BON’s operational history in natural active ingredients

Previous Partnership Reports

1 past event · Latest: Feb 17 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	R&D partnership	Positive	-0.6%	Joint laboratory deal for AI-driven natural ingredient bio-manufacturing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The only prior partnership announcement saw a modest negative reaction despite positive collaboration details, suggesting partnership news alone has not consistently driven upside.

Recent Company History

Over the past several months, BON combined product innovation with commercial and R&D partnerships. It signed large tea-pigment sales agreements worth US$26 million and $12 million, which coincided with small positive and one stronger 8.16% price move. It also launched a bio-manufacturing joint lab partnership that led to a slight -0.61% reaction. Today’s Tigerbone Group framework extends this partnership theme into traditional Chinese medicine and broader health-tech markets.

Key Terms

traditional Chinese medicine, life sciences, intellectual property rights

3 terms

traditional Chinese medicine medical

"advance collaboration in traditional Chinese medicine and life sciences through resource sharing"

A system of health care and remedies developed over centuries in China that uses herbal medicines, acupuncture, massage, diet and exercise to prevent or treat illness. For investors, it matters because products and services from this system form a sizeable consumer market and are subject to regulation, scientific scrutiny and supply-chain risks—similar to betting on a new gadget category where safety rules, proof of effectiveness and consumer trust drive sales.

life sciences medical

"advance collaboration in traditional Chinese medicine and life sciences through resource sharing"

Life sciences is a broad field that includes the study and development of products related to health, medicine, and biological systems. It covers areas such as pharmaceuticals, medical devices, and biotechnology, which aim to improve health and treat diseases. For investors, life sciences represent a sector with potential for innovation and growth, often driven by breakthroughs in science and technology.

intellectual property rights regulatory

"Each party will retain its independent intellectual property rights and scientific research achievements"

Legal protections that give a company exclusive control over creations like inventions, brand names, designs, formulas, software and creative works, similar to owning the lock and key to a recipe or product design. For investors, these rights matter because they can create durable revenue streams, reduce competition and justify higher company value, while weak or contested rights increase the risk of lost sales and costly legal disputes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

XI'AN, China, March 31, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, announced today that on February 4, 2026 it entered into a Cooperation Framework Agreement (the "Agreement") with Tigerbone Group Limited ("Tigerbone Group").  As part of this strategic initiative, the parties also announced plans to establish the "BON Cooperation and Development Committee," which will serve as a central platform to advance collaboration in traditional Chinese medicine and life sciences through resource sharing and complementary strengths.

Pursuant to the Agreement, and based on principles of equality, voluntariness, resource sharing, complementary advantages, and mutual benefit, BON and Tigerbone Group will collaborate across traditional Chinese medicine products, life sciences research, and nutritional functional foods. Each party will retain its independent intellectual property rights and scientific research achievements, while jointly developing new products, technologies, and solutions to drive innovation and long-term value creation.

Since its founding in 2006, BON has focused on the bio-manufacturing of natural active ingredients and the development of health solutions, growing into a globally recognized supplier in plant extracts, functional food ingredients, and personal care active ingredients. The Company's business footprint spans multiple regions, including China, North America, the European Union, Japan, and South Korea.

Tigerbone Group is a diversified investment holding company with significant industrial expertise and established market channels across traditional Chinese medicine, the broader health sector, and financial services.

Mr. Yongwei Hu, Chairman of BON, stated that the collaboration will integrate the respective brand and technological strengths of BON and Tigerbone Group, enabling resource consolidation and enhanced synergies. He added that the partnership represents a key step in BON's strategic expansion into the integration of traditional Chinese medicine and the broader health industry, as well as an important component of its global growth strategy.

Mr. Hu further noted: "Under the guidance of the 'BON Cooperation and Development Committee,' we expect to cultivate highly competitive new product categories under the BON brand within the health technology sector and deliver more scientifically grounded, natural health solutions to consumers worldwide. Looking ahead, BON and Tigerbone Group will continue to explore new technologies and innovations based on their existing intellectual property, with the goal of driving meaningful incremental market growth."

About Bon Natural Life Limited ("BON")

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit http://www.bnlus.com.

For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn 

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/bon-unveils-strategic-partnership-with-tigerbone-group-to-launch-new-natural-health-initiatives-302729701.html

SOURCE Bon Natural Life Limited

FAQ

What did BON (Nasdaq: BON) announce about the Tigerbone Group partnership on March 31, 2026?

BON announced a Cooperation Framework Agreement with Tigerbone Group signed February 4, 2026. According to the company, the agreement establishes the BON Cooperation and Development Committee to coordinate joint work in traditional Chinese medicine, life sciences research, and nutritional functional foods.

What is the role of the BON Cooperation and Development Committee under the BON–Tigerbone Group agreement?

The committee will serve as a central platform to advance collaboration and resource sharing. According to the company, it will guide joint product development, align research efforts, and consolidate brand and technological strengths to drive innovation.

Will BON and Tigerbone Group share intellectual property under the new Agreement?

Each party will retain its independent intellectual property rights while collaborating on new products. According to the company, existing IP and scientific research achievements remain with their original owners as they jointly develop technologies and solutions.

Which business areas will BON and Tigerbone Group focus on together under the Agreement?

The partnership targets traditional Chinese medicine, life sciences research, and nutritional functional foods. According to the company, collaboration spans product development, technology innovation, and complementary resource sharing across these areas.

How does the partnership with Tigerbone Group affect BON's global strategy and market presence?

The collaboration supports BON's strategic expansion into integrated health and TCM markets and global growth. According to the company, combining BON's bio-ingredient capabilities with Tigerbone's market channels aims to cultivate competitive product categories under the BON brand.